ABSTRACT
α1-Antitrypsin deficiency is a common genetic disease in which individuals homozygous for the mutant Z allele are at risk for the development of liver disease and emphysema. The mutant Z protein product is synthesized in hepatocytes but then accumulates intracellularly rather then being appropriately secreted. The effects of the intracellular accumulation of the mutant Z protein in the liver include the formation of protein polymers, activation of autophagy, mitochondrial injury, and caspase activation, which progress in a cascade causing hepatocellular injury. Liver disease can occur at any age, although the majority of children are free of significant liver dysfunction. The variable clinical presentations suggest an important contribution of genetic and environmental disease modifiers. The heterozygous carrier state for the mutant Z gene, present in 1.5% to 3% of the population, is not itself a common cause of liver injury but may be a modifier gene for other liver diseases.
KEYWORDS
α1-Antitrypsin - autophagy - apoptosis
REFERENCES
-
1
Teckman J H, Lindblad D.
Alpha-1-antitrypsin deficiency: diagnosis, pathophysiology, and management.
Curr Gastroenterol Rep.
2006;
8
14-20
-
2
Rudnick D A, Liao Y, An J K, Muglia L J, Perlmutter D H, Teckman J H.
Analyses of hepatocellular proliferation in a mouse model of alpha-1-antitrypsin deficiency.
Hepatology.
2004;
39
1048-1055
-
3
American Thoracic Society/European Respiratory Society Statement .
Standards for the diagnosis and management of individuals with alpha-1 antitrypsin deficiency.
Am J Respir Crit Care Med.
2003;
168
818-900
-
4
Qu D, Teckman J H, Perlmutter D H.
Review: alpha 1-antitrypsin deficiency associated liver disease.
J Gastroenterol Hepatol.
1997;
12
404-416
-
5
Eriksson S.
Discovery of alpha 1-antitrypsin deficiency.
Lung.
1990;
168(suppl)
523-529
-
6
Eriksson S.
Alpha 1-antitrypsin deficiency.
J Hepatol.
1999;
30(suppl 1)
34-39
-
7
Eriksson S.
A 30-year perspective on alpha 1-antitrypsin deficiency.
Chest.
1996;
110(suppl)
237S-242S
-
8
Perlmutter D H.
Alpha-1-antitrypsin deficiency: diagnosis and treatment.
Clin Liver Dis.
2004;
8
839-859
-
9
Sveger T.
Liver disease in alpha1-antitrypsin deficiency detected by screening of 200,000 infants.
N Engl J Med.
1976;
294
1316-1321
-
10
Sveger T.
Alpha 1-antitrypsin deficiency in early childhood.
Pediatrics.
1978;
62
22-25
-
11
An J K, Blomenkamp K, Lindblad D, Teckman J H.
Quantitative isolation of alphalAT mutant Z protein polymers from human and mouse livers and the effect of heat.
Hepatology.
2005;
41
160-167
-
12
Sveger T, Eriksson S.
The liver in adolescents with alpha 1-antitrypsin deficiency.
Hepatology.
1995;
22
514-517
-
13
Sveger T.
The natural history of liver disease in alpha 1-antitrypsin deficient children.
Acta Paediatr Scand.
1988;
77
847-851
-
14
Mowat A P.
Alpha 1-antitrypsin deficiency (PiZZ): features of liver involvement in childhood.
Acta Paediatr Suppl.
1994;
393
13-17
-
15
Pittschieler K, Massi G.
Alpha 1 antitrypsin deficiency in two population groups in north Italy.
Padiatr Padol.
1988;
23
307-311
-
16 Eriksson S. Alpha-1-antitrypsin deficiency: natural course and therapeutic strategies. In: Boyer JL, Blum HE, Maier K-P, Sauerbruch T, Stalder GA Falk Symposium 115: Liver Cirrhosis and Its Development. Dordrecht; Kluwer Academic Publishers 2001: 307-315
-
17
Sveger T, Piitulainen E, Arborelius Jr M.
Lung function in adolescents with alpha 1-antitrypsin deficiency.
Acta Paediatr.
1994;
83
1170-1173
-
18
Eden E, Hammel J, Rouhani F N et al..
Asthma features in severe alpha1-antitrypsin deficiency: experience of the National Heart, Lung, and Blood Institute Registry.
Chest.
2003;
123
765-771
-
19
Lomas D A, Finch J T, Seyama K, Nukiwa T, Carrell R W.
Alpha 1-antitrypsin Siiyama (Ser53→Phe): further evidence for intracellular loop-sheet polymerization.
J Biol Chem.
1993;
268
15333-15335
-
20
Lomas D A, Elliott P R, Sidhar S K et al..
Alpha 1-antitrypsin Mmalton (Phe52-deleted) forms loop-sheet polymers in vivo: evidence for the C sheet mechanism of polymerization.
J Biol Chem.
1995;
270
16864-16870
-
21
Laurell C B, Sveger T.
Mass screening of newborn Swedish infants for alpha antitrypsin deficiency.
Am J Hum Genet.
1975;
27
213-217
-
22
Sveger T, Thelin T, McNeil T F.
Young adults with alpha 1-antitrypsin deficiency identified neonatally: their health, knowledge about and adaptation to the high-risk condition.
Acta Paediatr.
1997;
86
37-40
-
23
McNeil T F, Sveger T, Thelin T.
Psychosocial effects of screening for somatic risk: the Swedish alpha 1 antitrypsin experience.
Thorax.
1988;
43
505-507
-
24
Piitulainen E, Sveger T.
Respiratory symptoms and lung function in young adults with severe alpha(1)-antitrypsin deficiency (PiZZ).
Thorax.
2002;
57
705-708
-
25
Teckman J H.
Lack of effect of oral 4-phenylbutyrate on serum alpha-1-antitrypsin in patients with alpha-1-antitrypsin deficiency: a preliminary study.
J Pediatr Gastroenterol Nutr.
2004;
39
34-37
-
26
Duan Y Y, Wu J, Zhu J L et al..
Gene therapy for human alpha1-antitrypsin deficiency in an animal model using SV40-derived vectors.
Gastroenterology.
2004;
127
1222-1232
-
27
Lomas D A, Mahadeva R.
Alpha1-antitrypsin polymerization and the serpinopathies: pathobiology and prospects for therapy.
J Clin Invest.
2002;
110
1585-1590
-
28
Wu Y, Whitman I, Molmenti E, Moore K, Hippenmeyer P, Perlmutter D H.
A lag in intracellular degradation of mutant alpha 1-antitrypsin correlates with the liver disease phenotype in homozygous PiZZ alpha 1-antitrypsin deficiency.
Proc Natl Acad Sci USA.
1994;
91
9014-9018
-
29
Qu D, Teckman J H, Omura S, Perlmutter D H.
Degradation of a mutant secretory protein, alpha1-antitrypsin Z, in the endoplasmic reticulum requires proteasome activity.
J Biol Chem.
1996;
271
22791-22795
-
30
Dafforn T R, Mahadeva R, Elliott P R, Sivasothy P, Lomas D A.
A kinetic mechanism for the polymerization of alpha1-antitrypsin.
J Biol Chem.
1999;
274
9548-9555
-
31
Lomas D A, Evans D L, Finch J T, Carrell R W.
The mechanism of Z alpha 1-antitrypsin accumulation in the liver.
Nature.
1992;
357
605-607
-
32
Cabral C M, Choudhury P, Liu Y, Sifers R N.
Processing by endoplasmic reticulum mannosidases partitions a secretion-impaired glycoprotein into distinct disposal pathways.
J Biol Chem.
2000;
275
25015-25022
-
33
Teckman J H, Burrows J, Hidvegi T, Schmidt B, Hale P D, Perlmutter D H.
The proteasome participates in degradation of mutant alpha 1-antitrypsin Z in the endoplasmic reticulum of hepatoma-derived hepatocytes.
J Biol Chem.
2001;
276
44865-44872
-
34
Teckman J H, Perlmutter D H.
Retention of mutant alpha(1)-antitrypsin Z in endoplasmic reticulum is associated with an autophagic response.
Am J Physiol Gastrointest Liver Physiol.
2000;
279
G961-G974
-
35
Sifers R N.
Cell biology: protein degradation unlocked.
Science.
2003;
299
1330-1331
-
36
Lomas D A, Parfrey H.
Alpha1-antitrypsin deficiency. 4: molecular pathophysiology.
Thorax.
2004;
59
529-535
-
37
Perlmutter D H.
Alpha1-antitrypsin deficiency: liver disease associated with retention of a mutant secretory glycoprotein in the endoplasmic reticulum.
Methods Mol Biol.
2003;
232
39-56
-
38
Lomas D A, Evans D L, Stone S R, Chang W S, Carrell R W.
Effect of the Z mutation on the physical and inhibitory properties of alpha 1-antitrypsin.
Biochemistry.
1993;
32
500-508
-
39
Lin L, Schmidt B, Teckman J, Perlmutter D H.
A naturally occurring nonpolymerogenic mutant of alpha 1-antitrypsin characterized by prolonged retention in the endoplasmic reticulum.
J Biol Chem.
2001;
276
33893-33898
-
40
Wu Y, Swulius M T, Moremen K W, Sifers R N.
Elucidation of the molecular logic by which misfolded alpha 1-antitrypsin is preferentially selected for degradation.
Proc Natl Acad Sci USA.
2003;
100
8229-8234
-
41
Lawless M W, Greene C M, Mulgrew A, Taggart C C, O'Neill S J, McElvaney N G.
Activation of endoplasmic reticulum-specific stress responses associated with the conformational disease Z alpha 1-antitrypsin deficiency.
J Immunol.
2004;
172
5722-5726
-
42
Teckman J H, An J K, Blomenkamp K, Schmidt B, Perlmutter D.
Mitochondrial autophagy and injury in the liver in alpha 1-antitrypsin deficiency.
Am J Physiol Gastrointest Liver Physiol.
2004;
286
G851-G862
-
43
Teckman J H, An J K, Loethen S, Perlmutter D H.
Fasting in alpha1-antitrypsin deficient liver: constitutive [correction of consultative] activation of autophagy.
Am J Physiol Gastrointest Liver Physiol.
2002;
283
G1156-G1165
-
44
Teckman J H, Perlmutter D H.
The endoplasmic reticulum degradation pathway for mutant secretory proteins alpha1-antitrypsin Z and S is distinct from that for an unassembled membrane protein.
J Biol Chem.
1996;
271
13215-13220
-
45
Marcus N Y, Perlmutter D H.
Glucosidase and mannosidase inhibitors mediate increased secretion of mutant alpha1 antitrypsin Z.
J Biol Chem.
2000;
275
1987-1992
-
46
Rudnick D A, Shikapwashya O, Blomenkamp K, Teckman J H.
Indomethacin increases liver damage in a murine model of liver injury from alpha-1-antitrypsin deficiency.
Hepatology.
2006;
44
976-982
-
47
Pittschieler K.
Liver disease and heterozygous alpha-1-antitrypsin deficiency.
Acta Paediatr Scand.
1991;
80
323-327
-
48
Kaserbacher R, Propst T, Propst A, Graziadei I, Judmaier G, Vogel W.
Association between heterozygous alpha 1-antitrypsin deficiency and genetic hemochromatosis.
Hepatology.
1993;
18
707-708
-
49
Propst T, Propst A, Dietze O, Judmaier G, Braunsteiner H, Vogel W.
High prevalence of viral infection in adults with homozygous and heterozygous alpha 1-antitrypsin deficiency and chronic liver disease.
Ann Intern Med.
1992;
117
641-645
-
50
Mahadeva R, Chang W S, Dafforn T R et al..
Heteropolymerization of S, I, and Z alpha1-antitrypsin and liver cirrhosis.
J Clin Invest.
1999;
103
999-1006
Jeffrey H TeckmanM.D.
Department of Pediatrics, St. Louis University, Cardinal Glennon Children's Medical Center
1465 South Grand Blvd., St. Louis, MO 63104
